Faruqi & Faruqi, LLP Announces Class Action Lawsuit Against Vistagen Investors
On January 18, 2026, Faruqi & Faruqi, LLP, a prominent national securities law firm, publicly announced its investigation into potential claims against Vistagen Therapeutics, Inc. (NASDAQ: VTGN). This comes in light of significant concerns regarding the company’s disclosures related to its Phase 3 PALISADE-3 trial of fasedienol, which aimed to treat social anxiety disorder (SAD) but failed to provide expected results.
The legal team at Faruqi & Faruqi emphasizes a crucial deadline for investors—March 16, 2026—when individuals can seek to become lead plaintiffs in a class action lawsuit that has been initiated against Vistagen. Investors who purchased or acquired securities from Vistagen between April 1, 2024, and December 16, 2025, are encouraged to contact the firm directly to discuss their legal options.
Vistagen Therapeutics has been under scrutiny recently due to its unsuccessful clinical trials, particularly the results reported on December 17, 2025. The PALISADE-3 study aimed to evaluate the efficacy of fasedienol in addressing acute symptoms of social anxiety disorder. However, the trial did not meet its primary efficacy endpoints, as the company stated it "did not demonstrate statistically significant improvement on primary endpoint of reduction in anxiety as measured by SUDS scores compared to placebo."
Following this announcement, Vistagen's stock price plummeted by $3.50, a staggering 80.27% decline, closing at $0.86. Investors were understandably alarmed, leading to increased calls for accountability from the company’s executives. The complaint filed alleges that Vistagen and its leadership violated federal securities laws by issuing misleading statements and not disclosing critical adverse information regarding the trial results.
Faruqi & Faruqi, LLP specializes in representing investors in cases of securities fraud. Founded in 1995, the firm has successfully recovered hundreds of millions of dollars for clients. The firm invites any current or former shareholders, whistleblowers, or anyone with insider information related to Vistagen's actions to come forward and provide insights that could strengthen the class action case.
James (Josh) Wilson, a partner at Faruqi & Faruqi, has been leading these efforts, encouraging affected investors to reach out. “The impact of misleading information on investors cannot be understated,” he stated. “We are committed to seeking the justice our clients deserve.”
Potential lead plaintiffs are individuals who have the largest financial interest in the actions sought by the class and are representative of the class members. They can approach the court to step into this crucial role, or they may opt to remain as absent class members. The ultimate goal is to secure proper legal redress for all investors affected by Vistagen’s actions. The appeal is clear: investors damaged by Vistagen's alleged misconduct are urged to take action.
Investors wishing to take part in the class action lawsuit or those who simply need to gather more information can do so by visiting Faruqi & Faruqi’s website or by contacting Josh Wilson directly at 877-247-4292 or 212-983-9330, extension 1310. The firm assures confidentiality throughout the process.
For continuous updates, you can follow Faruqi & Faruqi on LinkedIn, X, or Facebook. As the legal landscape develops, staying informed is pivotal for all involved. Through these efforts, there is hope for recuperation of losses faced by investors as Vistagen navigates these tumultuous waters. Remember, the deadline to act is fast approaching, and every investor’s voice matters.
In conclusion, this class action lawsuit against Vistagen represents more than just a financial battle; it embodies a stand for accountability in the biotech industry where many lives and investments are intertwined. By banding together, affected stakeholders can exert significant pressure for transparency and integrity in corporate conduct.
The legal team at Faruqi & Faruqi emphasizes a crucial deadline for investors—March 16, 2026—when individuals can seek to become lead plaintiffs in a class action lawsuit that has been initiated against Vistagen. Investors who purchased or acquired securities from Vistagen between April 1, 2024, and December 16, 2025, are encouraged to contact the firm directly to discuss their legal options.
Background on Vistagen
Vistagen Therapeutics has been under scrutiny recently due to its unsuccessful clinical trials, particularly the results reported on December 17, 2025. The PALISADE-3 study aimed to evaluate the efficacy of fasedienol in addressing acute symptoms of social anxiety disorder. However, the trial did not meet its primary efficacy endpoints, as the company stated it "did not demonstrate statistically significant improvement on primary endpoint of reduction in anxiety as measured by SUDS scores compared to placebo."
Following this announcement, Vistagen's stock price plummeted by $3.50, a staggering 80.27% decline, closing at $0.86. Investors were understandably alarmed, leading to increased calls for accountability from the company’s executives. The complaint filed alleges that Vistagen and its leadership violated federal securities laws by issuing misleading statements and not disclosing critical adverse information regarding the trial results.
The Role of Faruqi & Faruqi, LLP
Faruqi & Faruqi, LLP specializes in representing investors in cases of securities fraud. Founded in 1995, the firm has successfully recovered hundreds of millions of dollars for clients. The firm invites any current or former shareholders, whistleblowers, or anyone with insider information related to Vistagen's actions to come forward and provide insights that could strengthen the class action case.
James (Josh) Wilson, a partner at Faruqi & Faruqi, has been leading these efforts, encouraging affected investors to reach out. “The impact of misleading information on investors cannot be understated,” he stated. “We are committed to seeking the justice our clients deserve.”
Potential lead plaintiffs are individuals who have the largest financial interest in the actions sought by the class and are representative of the class members. They can approach the court to step into this crucial role, or they may opt to remain as absent class members. The ultimate goal is to secure proper legal redress for all investors affected by Vistagen’s actions. The appeal is clear: investors damaged by Vistagen's alleged misconduct are urged to take action.
How to Get Involved
Investors wishing to take part in the class action lawsuit or those who simply need to gather more information can do so by visiting Faruqi & Faruqi’s website or by contacting Josh Wilson directly at 877-247-4292 or 212-983-9330, extension 1310. The firm assures confidentiality throughout the process.
For continuous updates, you can follow Faruqi & Faruqi on LinkedIn, X, or Facebook. As the legal landscape develops, staying informed is pivotal for all involved. Through these efforts, there is hope for recuperation of losses faced by investors as Vistagen navigates these tumultuous waters. Remember, the deadline to act is fast approaching, and every investor’s voice matters.
In conclusion, this class action lawsuit against Vistagen represents more than just a financial battle; it embodies a stand for accountability in the biotech industry where many lives and investments are intertwined. By banding together, affected stakeholders can exert significant pressure for transparency and integrity in corporate conduct.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.